Mechanism of action at the cellular level
The drug exerts its effect in the small intestine at the level of the villi and the brush border of enterocytes. Epithelial cells are interconnected by tight junctions that ensure membrane polarity. On the apical surface, ezetimibe specifically interferes with the sterol transport system:
- Inhibition of uptake: The drug blocks the specific NPC1L1 (Niemann-Pick C1-Like 1) transporter, halting the uptake of dietary and biliary cholesterol from the intestinal lumen into the enterocyte.
- Activation of efflux: It stimulates ATP-binding cassette transporters ABCG5 and ABCG8, which actively pump sterols back into the intestinal lumen.
As a result, cholesterol influx into enterocytes is reduced, subsequently decreasing its delivery to the liver via chylomicrons.
Pharmacokinetic features
Once in the body, the drug undergoes important transformations:
- Approximately 80% of the dose is metabolized to form an active metabolite, ezetimibe-glucuronide.
- The compound actively participates in enterohepatic circulation.
- Due to continuous recirculation between the intestine and the liver, the drug is retained in the body for a prolonged period, with a half-life of approximately 22 hours.
Clinical use and combinations
Ezetimibe is available as a single-ingredient drug and is also part of combination products (e.g., brand names Ezetrol, Edi, Mertenil):
- Monotherapy: Reduces hypercholesterolemia by approximately 18%.
- Combinations: Maximum efficacy is achieved when co-administered with simvastatin. There is a fixed combination, Vytorin, containing 10 mg of ezetimibe and 10 to 80 mg of simvastatin.
- Additional effect: The drug exhibits pleiotropic anti-inflammatory properties, reducing plasma C-reactive protein concentrations by more than half.
Briefly: answers to topical questions
By what percentage does ezetimibe reduce LDL cholesterol levels in monotherapy?
In monotherapy, the drug reduces overall hypercholesterolemia by 18%. Precise data on the percentage reduction exclusively for low-density lipoprotein (LDL) cholesterol in monotherapy are not specified in the sources. The effect is achieved through the selective inhibition of dietary and biliary cholesterol absorption in enterocytes via blockade of the specific NPC1L1 transporter.
What are the absolute contraindications to prescribing ezetimibe?
Sources indicate that in liver cirrhosis, ezetimibe therapy must be discontinued upon the appearance of signs of decompensation corresponding to Child–Pugh class B–C. When ezetimibe is combined with HMG-CoA reductase inhibitors, monitoring of transaminases (ALT, AST) is mandatory; decisions regarding discontinuation or dosage adjustment upon their elevation are made in accordance with the statin prescribing information.
Which lipid-lowering agents, other than statins, can be rationally combined with ezetimibe?
Ezetimibe can be used in combination with PCSK9 inhibitors—alirocumab and evolocumab—or with inclisiran, particularly when target LDL-C levels are not achieved or in cases of statin intolerance. In non-alcoholic fatty liver disease (NAFLD) experimental models, the combination of ursodeoxycholic acid + rosuvastatin + ezetimibe has been studied, demonstrating a reduction in ALT along with anti-apoptotic and antifibrotic effects.
Ezetimibe = "Ezet-NPC" (blocks uptake via NPC1L1, pumps out via ABCG5/8 back into the intestinal lumen).
Class and exam questions
Which protein is the primary target of ezetimibe?
The main target is the specific transporter protein NPC1L1 on the apical membrane of enterocytes, responsible for cholesterol transport into the cell.
What is the role of the ABCG5 and ABCG8 transporters?
These ATP-binding cassette transporters are stimulated by the drug and efflux sterols from the enterocyte back into the intestinal lumen.
Which statin is most effective to combine with ezetimibe?
Combination therapy with simvastatin is the most effective, also available as the fixed-dose medication Vytorin.
What else to study on this topic
- The role of tight junctions (zonula occludens) in maintaining enterocyte polarity
- Structure and functions of chylomicrons in exogenous lipid transport
- Mechanisms of enterohepatic circulation of drugs
- Pleiotropic effects of lipid-lowering agents and reduction of C-reactive protein
- Comparative characteristics of monotherapy and combination regimens in dyslipidemias
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Ezetimibe" and 5,304 other pages of the subject
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the section "Drugs used in atherosclerosis"
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.